Influenza

Mike Ison, MD, MS, discusses the key takeaways from the CAPSTONE-2 phase 3 trial evaluating baloxavir marboxil for the treatment of patients with influenza.

Today, the US Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours.

The phase 3 CAPSTONE-2 trial shows treatment with baloxavir marboxil significantly reduced the time to improvement of flu symptoms compared with placebo.

The US Food and Drug Administration (FDA) has extended approval for the use of AFLURIA quadrivalent influenza vaccine in individuals 6 months and older.

As knowledge and awareness of rising antimicrobial resistance increase, clinicians must continue to adopt strategies for improving antibiotic use.

A new report on influenza vaccination rates among US health care workers finds that employer requirements help keep vaccination rates of health care workers higher than that of the general public.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Mindy Smith, BSPharm, RPh, provides tips for recommending the flu shot to patients who are more likely to get the flu.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

Contamination is a common aspect of nasal saline irrigations.

New research published in The BMJ indicates that the Pandemrix vaccine was linked with 5 times the number of adverse events reported from 2 other pandemic vaccines.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

The NIAID is sponsoring a phase 1 clinical trial to assess if a nasal influenza vaccine candidate used in combination with a licensed vaccine can enhance immune responses against influenza in children and teens.

Adding reminders to electronic health records shows promise at improving influenza vaccination rates, according to results of JAMA Open Network study.

The possibility of a new antiviral class administered as a single oral dose that is well tolerated will be a welcome addition to the treatment armamentarium for #influenza. However, its use should be limited to carefully selected individuals.

Mindy Smith, BSPharm, RPh, shares common misconceptions about the flu shot and how providers can advocate for the vaccination to their patients.

Public Health England recommends individuals at higher risks for influenza receive a newly available adjuvanted trivalent influenza vaccine this winter.

Investigators from the NIH have launched a phase 1 clinical trial to assess if a topical cream administered prior to H5N1 vaccination can enhance immune response.

Troy Trygstad, PharmD, MBA, PhD, discusses the trends of targeted research in the influenza vaccination space and how protocols could differ based off of variances.

New research finds that the flu vaccine is more successful in women than in men, but the complexity of the issue makes it difficult to know exactly why that is.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

A new study by St. Jude Children’s Research Hospital reported that gamma delta (γδ) T cells play a key role in protecting infants from flu complications.

A universal flu vaccine candidate elicits protective response in mice against multiple strains of the virus.

In a wounded mouse model concurrently infected with influenza A, investigators observed that the innate immune system prioritized responding to the lung infection, delaying wound healing.

New recommendations from the CDC's Advisory Committee on Immunization Practices reveal that health care providers have the intranasally-administered live attenuated influenza vaccine (LAIV) among their arsenal of available vaccines for the 2018-2019 flu season.